Overview | Analyst Coverage | Press Releases | Events & Presentations
Governance | SEC Filings | Annual Reports and Proxy Statement | Key Ratios
Stock Performance | Contact Us
Governance | SEC Filings | Annual Reports and Proxy Statement | Key Ratios
Stock Performance | Contact Us
Investor Relations
Corporate ProfileCatalyst Pharmaceutical Partners of Coral Gables, Florida, is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. Catalyst has been granted an exclusive worldwide license from Brookhaven National Laboratory to nine U.S. patents and two U.S. patent applications relating to the use of vigabatrin for the treatment of a wide variety of substance abuses. Catalyst's product development efforts are currently focused on the development of vigabatrin (designated CPP-109 by Catalyst) as a treatment for cocaine and methamphetamine addiction. Annual Reports and Proxy Statement Recent Releases02/25/10Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference 02/23/10 Catalyst Pharmaceutical Partners and The National Institute on Drug Abuse Plan to Initiate U.S. Phase II(b) Clinical Trial for Cocaine Addiction Events02/25/102010 Epilepsy Pipeline Update Conference Presentation 02/23/10 Catalyst Pharmaceutical Conference Call |
Stock Information
Data delayed at least 20 min.
Shareholder Tools
|
||||||||
